Terms: = Ovarian cancer AND ER, estrogen receptor AND Clinical Outcome
31 results:
1. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract] [Full Text] [Related]
2. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
3. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
Liu X; Viswanadhapalli S; Kumar S; Lee TK; Moore A; Ma S; Chen L; Hsieh M; Li M; Sareddy GR; Parra K; Blatt EB; Reese TC; Zhao Y; Chang A; Yan H; Xu Z; Pratap UP; Liu Z; Roggero CM; Tan Z; Weintraub ST; Peng Y; Tekmal RR; Arteaga CL; Lippincott-Schwartz J; Vadlamudi RK; Ahn JM; Raj GV
Nat Cancer; 2022 Jul; 3(7):866-884. PubMed ID: 35654861
[TBL] [Abstract] [Full Text] [Related]
4. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Rajan A; Nadhan R; Latha NR; Krishnan N; Warrier AV; Srinivas P
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188482. PubMed ID: 33260050
[TBL] [Abstract] [Full Text] [Related]
5. Significance of ERCC1 and Hormonal receptor Expression in ovarian cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma.
Samanta S; Tamura S; Dubeau L; Mhawech-Fauceglia P; Miyagi Y; Kato H; Lieberman R; Buckanovich RJ; Lin YG; Neamati N
Sci Rep; 2020 Feb; 10(1):2160. PubMed ID: 32034256
[TBL] [Abstract] [Full Text] [Related]
7. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
[TBL] [Abstract] [Full Text] [Related]
8. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y; Trillo-Tinoco J; Sierra RA; Anadon C; Dai W; Mohamed E; Cen L; Costich TL; Magliocco A; Marchion D; Klar R; Michel S; Jaschinski F; Reich RR; Mehrotra S; Cubillos-Ruiz JR; Munn DH; Conejo-Garcia JR; Rodriguez PC
Nat Commun; 2019 Mar; 10(1):1280. PubMed ID: 30894532
[TBL] [Abstract] [Full Text] [Related]
9. ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.
Kirn V; Strake L; Thangarajah F; Richters L; Eischeid H; Koitzsch U; Odenthal M; Fries J
Clin Exp Metastasis; 2018 Oct; 35(7):707-712. PubMed ID: 30173322
[TBL] [Abstract] [Full Text] [Related]
10. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L; Mastoraki S; Buderath P; Strati A; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Gynecol Oncol; 2018 Aug; 150(2):355-360. PubMed ID: 29807696
[TBL] [Abstract] [Full Text] [Related]
11. The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer.
Carberry S; D'Orsi B; Monsefi N; Salvucci M; Bacon O; Fay J; Rehm M; McNamara D; Kay EW; Prehn JHM
Cell Death Dis; 2018 Jan; 9(2):125. PubMed ID: 29374142
[TBL] [Abstract] [Full Text] [Related]
12. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
[TBL] [Abstract] [Full Text] [Related]
13. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
[TBL] [Abstract] [Full Text] [Related]
14. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract] [Full Text] [Related]
15. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
[TBL] [Abstract] [Full Text] [Related]
16. estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract] [Full Text] [Related]
17. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary.
Hutton SM; Webster LR; Nielsen S; Leung Y; Stewart CJ
Pathology; 2012 Dec; 44(7):611-6. PubMed ID: 23149378
[TBL] [Abstract] [Full Text] [Related]
19. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
[TBL] [Abstract] [Full Text] [Related]
20. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract] [Full Text] [Related]
[Next]
